IP Library Patent Application 12398827
Patent Application
App. No. 12/398,827

METHOD FOR DETECTING RARE EVENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/398,827
Abstract

Provided are methods, compositions and kits for efficiently and accurately identifying rare events in a biological sample.

Claims (22)

1 . A method for identifying proliferative disorders in a biological sample, comprising:

contacting an obtained source of cells with a binding agent specific for a cell specific marker associated with a proliferative disorder and expressed by at least some of the cells, wherein the binding agent is bound to a magnetic bead and wherein the binding agent binds to cells in the source expressing the cell specific marker;

separating cells bound by the binding agent from the source thereby obtaining a sub-population of cells enriched for the cell specific marker associated with the proliferative disorder;

placing the enriched sample on a microscope slide;

automatically scanning the microscope slide at a plurality of coordinates using a microscope;

automatically obtaining a plurality of images at locations on the microscope slide that comprise the enriched sample; and

processing each of the plurality of images to identify the proliferative disorder, including transforming the images to a different color space, thresholding the images, and determining the presence of one or more regions of connected pixels having the same color in the thresholded images.

2 . The method according to claim 1 , wherein the binding agent is an antibody.

3 . The method according to claim 1 , wherein the sub-population is enriched for carcinoma cells.

4 . The method of claim 1 , wherein the separating is done by positive selection.

5 . The method of claim 1 , wherein the separating is done by negative selection.

6 . The method of claim 2 , wherein the antibody is monoclonal or polyclonal.

7 . The method of claim 2 , wherein the antibody recognizes an epithelial marker.

8 . The method of claim 2 , wherein the antibody is selected to avoid cross reactivity with the beads.

9 . The method of claim 3 , wherein the carcinoma cells are from peripheral blood.

10 . The method of claim 1 , further comprising:

(a) automatically identifying a coordinate of the proliferative disorder; and

(b) automatically acquiring an image of the proliferative disorder, at the location coordinates.

11 . The method of claim 1 , wherein the proliferative disorder is detected by immunohistochemistry.

12 . The method of claim 1 , wherein the proliferative disorder is detected by in situ hybridization.

13 . The method of claim 1 , wherein the cell specific marker is detected by immunohistochemistry, in situ hybridization, staining or a combination thereof.

14 . The method of claim 1 , wherein the image is a digital image.

Assignments (1)
ASSET PURCHASE AGREEMENT Recorded Jul 27, 2009
From: CARL ZEISS MICROIMAGING AIS, INC
To: CARL ZEISS MICROIMAGING GMBH
Reel/Frame 023011/0020 →